share_log

HC Wainwright & Co. Reiterates Buy on Entrada Therapeutics, Maintains $25 Price Target

Benzinga ·  Aug 2, 2023 06:20

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Entrada Therapeutics (NASDAQ:TRDA) with a Buy and maintains $25 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment